US Surgeon General Calls for Cancer Warnings on Alcohol

More like this

• Food09/27/2026@DrinksDesk

  Ireland Signs the World's First Alcohol Health Warning Label Law

  Miesian Plaza, James's Place East, South Dock Ward 1986, Dublin, County Dublin, Leinster, D02 XW14, Éire / IrelandGovernment of Ireland

  

  Starts 05/22/2023CONFIRMED85% CONFIDENCE3.4 years agoThe Department of Health release, 'Published on: 22 May 2023', says 'The Minister for Health Stephen Donnelly has signed into law the Public Health (Alcohol) (Labelling) Regulations 2023'.^[1]

  Health Minister Stephen Donnelly signs regulations requiring every alcohol container sold in Ireland to warn of liver disease, fatal cancers and drinking in pregnancy and to show grams of alcohol and calories, from 22 May 2026.

  0.68

  00
• Food09/27/2026@DrinksDesk

  Ireland's Alcohol Health Warning Labels Take Effect

  Miesian Plaza, James's Place East, South Dock Ward 1986, Dublin, County Dublin, Leinster, D02 XW14, Éire / IrelandGovernment of Ireland

  

  Starts 09/03/2028DELAYED2.5 years late68% CONFIDENCEin 1.9 yearsS.I. 422/2025, given on 3 September 2025, says Section 12 'shall come into operation 3 years after the date on which this Order is made', which Arthur Cox^[3] reads as 3 September 2028.

  Cancer, liver-disease and pregnancy warnings become mandatory on every alcohol container sold in Ireland, after the government pushed the start from 22 May 2026 to 3 September 2028 citing economic circumstances.

  0.66

  00
• Food09/27/2026@HealthDesk

  National Academies Publish Their Review of Evidence on Alcohol and Health

  National Academy of Sciences, 500, 5th Street Northwest, Downtown East, Penn Quarter, Ward 2, Washington, District of Columbia, 20001, United StatesNational Academies of Sciences, Engineering, and Medicine

  

  Starts 12/17/2024CONFIRMED85% CONFIDENCE1.8 years agoThe National Academies^[1][2][4]' news release is marked 'Last update December 17, 2024' and datelined WASHINGTON, announcing 'A new report from the National Academies'.

  A Congress-ordered National Academies report finds with moderate certainty that moderate drinking is linked to lower all-cause mortality but a higher risk of female breast cancer, evidence meant to inform the 2025-2030 Dietary Guidelines for Americans.

  0.65

  00
• Health09/25/2026@HealthDesk

  HHS and FDA Move to Strip Boxed Warnings From Menopause Hormone Therapy

  U.S. Department of Health and Human Services, 200, Independence Avenue Southwest, Ward 6, Washington, District of Columbia, 20201, United StatesU.S. Food and Drug Administration

  

  Starts 11/10/2025 4:09PMCONFIRMED86% CONFIDENCE322 days agoThe FDA^[1][3] news release is headed "For Immediate Release: November 10, 2025" and says Kennedy and Makary "made the announcement at a press conference at HHS"; CBS News' livestream of it began at 16:09 UTC.

  At an HHS press conference, Robert F. Kennedy Jr. and FDA Commissioner Marty Makary announce that the FDA will remove the breast cancer, heart disease and dementia boxed warnings that have covered menopausal hormone therapy since the early 2000s.

  0.63

  00
• Food09/27/2026@HealthDesk

  Dietary Guidelines for Americans 2025-2030 Drop the Daily Drink Limits

  U.S. Department of Health and Human Services, 200, Independence Avenue Southwest, Ward 6, Washington, District of Columbia, 20201, United StatesU.S. Department of Health and Human Services

  

  Starts 01/07/2026CONFIRMED88% CONFIDENCE264 days agoUSDA's^[1] release, 'Published: January 7, 2026', says HHS Secretary Robert F. Kennedy, Jr. and USDA Secretary Brooke Rollins 'today released the Dietary Guidelines for Americans, 2025-2030'.

  The new federal Dietary Guidelines tell Americans to 'consume less alcohol for better overall health' but no longer set the two-drinks-for-men, one-for-women daily limit that earlier editions carried.

  0.61

  00
• Health09/25/2026@HealthDesk

  FDA Approves First HRT Labels Without the Breast Cancer Boxed Warning

  Mahan Court, FDA White Oak Campus, White Oak, Montgomery County, Maryland, 20993, United StatesU.S. Food and Drug Administration

  

  Starts 02/12/2026CONFIRMED84% CONFIDENCE228 days agoThe FDA^[1][4] news release is headed "For Immediate Release: February 12, 2026" and says the FDA "has approved drug labeling changes to six menopausal hormone therapy products".

  The FDA approves new labels for six menopausal hormone therapy products, one from each class, that drop the cardiovascular, breast cancer and dementia statements from the boxed warning; 29 companies have filed changes.

  0.60

  00
• Health09/25/2026@HealthDesk

  FDA Decision Due on Roche's Giredestrant for Early Breast Cancer

  Mahan Court, FDA White Oak Campus, White Oak, Montgomery County, Maryland, 20993, United StatesRoche

  

  Starts 11/30/2026SCHEDULED78% CONFIDENCEin 63 daysRoche's^[1] release says "The FDA is expected to make a decision on the approval by 30 November 2026", the PDUFA goal date set under Priority Review.

  The FDA is due to decide by 30 November 2026 whether to approve Roche's giredestrant, an oral SERD that cut the risk of recurrence or death by 30% versus standard hormone therapy in early ER-positive breast cancer.

  0.60

  00
• Food09/27/2026@DrinksDesk

  Gallup Finds a Record-Low 54% of Americans Drink Alcohol

  The Gallup Building, 901, F Street Northwest, Penn Quarter, Ward 2, Washington, District of Columbia, 20004, United StatesGallup

  

  Starts 08/13/2025CONFIRMED86% CONFIDENCE1.1 years agoGallup's^[1][2] release is dated 'August 13, 2025' and datelined WASHINGTON, D.C.; the survey ran July 7-21.

  Gallup's annual Consumption Habits poll finds 54% of US adults drink, the lowest in its trend back to 1939, and for the first time a majority, 53%, say moderate drinking is bad for health.

  0.59

  00
• Food09/27/2026@DrinksDesk

  Gallup: Americans' Drinking Holds at a Record-Low 54%

  The Gallup Building, 901, F Street Northwest, Penn Quarter, Ward 2, Washington, District of Columbia, 20004, United StatesGallup

  

  Starts 08/20/2026CONFIRMED89% CONFIDENCE39 days agoGallup's^[1][2] release is dated 'August 20, 2026' and datelined WASHINGTON, D.C., from its July 1-19 Consumption Habits survey.

  Gallup's 2026 Consumption Habits poll finds 54% of US adults drink for a second straight year, a record-low 13% say they sometimes drink too much, and 17% have had non-alcoholic beer, wine or spirits instead of a drink in the past year.

  0.58

  00
• Health09/25/2026@HealthDesk

  FDA Rule Requiring Breast Density Notices With Every Mammogram Takes Effect

  Mahan Court, FDA White Oak Campus, White Oak, Montgomery County, Maryland, 20993, United StatesU.S. Food and Drug Administration

  

  Starts 09/10/2024CONFIRMED89% CONFIDENCE2.0 years agoThe FDA^[1] page says "Enforcement of the MQSA regulations as amended by the 2023 MQSA Final Rule began on September 10, 2024"; the rule has no end date, so the period is open-ended.

  Every US mammography facility must now tell patients in writing whether their breast tissue is dense, which can hide cancers on a mammogram, under the FDA's amended Mammography Quality Standards Act rule.

  0.58

  00
• Health09/25/2026@HealthDesk

  FDA Puts a Boxed Liver-Injury Warning on Menopause Drug Veozah

  Mahan Court, FDA White Oak Campus, White Oak, Montgomery County, Maryland, 20993, United StatesAstellas Pharma

  

  Starts 12/16/2024CONFIRMED87% CONFIDENCE1.8 years agoThe FDA^[1][5] drug safety communication carries the entry "12-16-2024 Update: FDA adds a Boxed Warning, our most prominent warning, to highlight the known risk of rare but serious liver injury".

  The FDA adds a boxed warning, its most prominent, to Astellas' hot-flash pill Veozah after a patient suffered serious liver injury within about 40 days of starting it, and orders monthly liver tests for the first months.

  0.58

  00
• Health09/23/2026@HealthDesk

  FDA Authorizes Abbott's Libre Duo Glucose-Ketone Sensor

  1360 South Loop Road, Alameda, Alameda County, California, 94502, United StatesAbbott Laboratories

  

  Starts 08/25/2026CONFIRMED87% CONFIDENCE34 days agoThe release is datelined "ABBOTT PARK, Ill., Aug. 25, 2026" and says Abbott "today announced U.S. Food and Drug Administration (FDA^[2][3]) authorization of its Libre Duo 10 Day system"; the FDA's De Novo record gives the same decision date, 08/25/2026.

  The FDA authorized Abbott's Libre Duo 10 Day, the first wearable to continuously track both glucose and ketones, which alerts people with diabetes aged 2 and older to rising ketones before diabetic ketoacidosis.

  0.57

  00